Tyck till om SwePub Sök här!
WFRF:(Hawryluk M.)
Sökning: WFRF:(Hawryluk M.) > Diagnostic pathways...
- 10 av 14
- Föregående post
- Nästa post
- Till träfflistan
Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data
-
- Vedsted, P (författare)
- Aarhus Univ, Dept Clin Med, Aarhus, Denmark.;Aarhus Univ, Dept Publ Hlth, Res Unit Gen Practice, Aarhus C, Denmark
-
- Weller, D (författare)
- Univ Edinburgh, Gen Practice, Edinburgh, Midlothian, Scotland
-
- Falborg, AZ (författare)
- Aarhus Univ, Dept Publ Hlth, Res Unit Gen Practice, Aarhus C, Denmark
- visa fler...
- visa färre...
- Aarhus Univ, Dept Clin Med, Aarhus, Denmark;Aarhus Univ, Dept Publ Hlth, Res Unit Gen Practice, Aarhus C, Denmark Univ Edinburgh, Gen Practice, Edinburgh, Midlothian, Scotland (creator_code:org_t)
- 2022-12-15
- 2022
- Engelska.
- Ingår i: BMJ open. - : BMJ. - 2044-6055. ; 12:12, s. e059669-
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- A growing body of evidence suggests longer time between symptom onset and start of treatment affects breast cancer prognosis. To explore this association, the International Cancer Benchmarking Partnership Module 4 examined differences in breast cancer diagnostic pathways in 10 jurisdictions across Australia, Canada, Denmark, Norway, Sweden and the UK.SettingPrimary care in 10 jurisdictions.ParticipantData were collated from 3471 women aged >40 diagnosed for the first time with breast cancer and surveyed between 2013 and 2015. Data were supplemented by feedback from their primary care physicians (PCPs), cancer treatment specialists and available registry data.Primary and secondary outcome measuresPatient, primary care, diagnostic and treatment intervals.ResultsOverall, 56% of women reported symptoms to primary care, with 66% first noticing lumps or breast changes. PCPs reported 77% presented with symptoms, of whom 81% were urgently referred with suspicion of cancer (ranging from 62% to 92%; Norway and Victoria). Ranges for median patient, primary care and diagnostic intervals (days) for symptomatic patients were 3–29 (Denmark and Sweden), 0–20 (seven jurisdictions and Ontario) and 8–29 (Denmark and Wales). Ranges for median treatment and total intervals (days) for all patients were 15–39 (Norway, Victoria and Manitoba) and 4–78 days (Sweden, Victoria and Ontario). The 10% longest waits ranged between 101 and 209 days (Sweden and Ontario).ConclusionsLarge international differences in breast cancer diagnostic pathways exist, suggesting some jurisdictions develop more effective strategies to optimise pathways and reduce time intervals. Targeted awareness interventions could also facilitate more timely diagnosis of breast cancer.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- 10 av 14
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Vedsted, P
- Weller, D
- Falborg, AZ
- Jensen, H
- Kalsi, J
- Brewster, D
- visa fler...
- Lin, YL
- Gavin, A
- Barisic, A
- Grunfeld, E
- Lambe, M
- Malmberg, M
- Turner, D
- Harland, E
- Hawryluk, B
- Law, RJ
- Neal, RD
- White, V
- Bergin, R
- Harrison, S
- Menon, U
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- BMJ open
- Av lärosätet
- Karolinska Institutet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
